[HTML][HTML] Combination of pre-treatment dynamic [18F]FET PET radiomics and conventional clinical parameters for the survival stratification in patients with IDH …
…, P Bartenstein, JC Tonn, M Unterrainer… - European Journal of …, 2023 - Springer
Purpose The aim of this study was to build and evaluate a prediction model which incorporates
clinical parameters and radiomic features extracted from static as well as dynamic [ 18 F]…
clinical parameters and radiomic features extracted from static as well as dynamic [ 18 F]…
[HTML][HTML] Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma
…, A Karl, CG Stief, ST Ledderose, M Unterrainer… - European Journal of …, 2022 - Springer
Background [ 68 Ga]Ga-FAPI-46 is a novel positron emission tomography (PET) ligand that
targets fibroblast activation protein (FAP) expression as FAP inhibitor (FAPI) and could …
targets fibroblast activation protein (FAP) expression as FAP inhibitor (FAPI) and could …
Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy
…, A Delker, F Völter, LM Unterrainer… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Radiopharmaceutical therapies (RPTs) with 177 Lu-prostate-specific membrane antigen (PSMA)
ligands have demonstrated promising results for the treatment of metastatic castration-…
ligands have demonstrated promising results for the treatment of metastatic castration-…
Prognostic Value of TSPO PET Before Radiotherapy in Newly Diagnosed IDH–Wild-Type Glioblastoma
…, M Niyazi, M Unterrainer… - Journal of Nuclear …, 2023 - Soc Nuclear Med
The 18-kDa translocator protein (TSPO) is gaining recognition as a relevant target in
glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging in …
glioblastoma imaging. However, data on the potential prognostic value of TSPO PET imaging in …
[HTML][HTML] Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial
A Holzgreve, M Unterrainer, J Calais, T Adams… - European journal of …, 2023 - Springer
Purpose The proPSMA trial at ten Australian centers demonstrated increased sensitivity and
specificity for PSMA PET/CT compared to conventional imaging regarding metastatic status …
specificity for PSMA PET/CT compared to conventional imaging regarding metastatic status …
[HTML][HTML] Longitudinal [18F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model
…, LM Bartos, LM Unterrainer, M Unterrainer… - Biomedicines, 2022 - mdpi.com
The 18 kDa translocator protein (TSPO) is increasingly recognized as an interesting target
for the imaging of glioblastoma (GBM). Here, we investigated TSPO PET imaging and …
for the imaging of glioblastoma (GBM). Here, we investigated TSPO PET imaging and …
[HTML][HTML] Reliability and practicability of PSMA-RADS 1.0 for structured reporting of PSMA-PET/CT scans in prostate cancer patients
…, C Burgard, C Schmid-Tannwald, LM Unterrainer… - European …, 2024 - Springer
Objectives As structured reporting is increasingly used in the evaluation of prostate-specific
membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) …
membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) …
Cost-effectiveness analysis of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer
…, A Herlemann, M Unterrainer… - Journal of the National …, 2023 - jnccn.org
Background: Metastatic castration-resistant prostate cancer poses a therapeutic challenge
with poor prognosis. The VISION trial showed prolonged progression-free and overall survival …
with poor prognosis. The VISION trial showed prolonged progression-free and overall survival …
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
LM Unterrainer, J Calais… - Annual Review of …, 2024 - annualreviews.org
Prostate-specific membrane antigen (PSMA) as a transmembrane protein is overexpressed
by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular-…
by prostate cancer (PC) cells and is accessible for binding antibodies or low-molecular-…
[HTML][HTML] Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac …
…, CG Stief, P Bartenstein, H Ilhan, M Unterrainer - Biomedicines, 2022 - mdpi.com
Background: PSMA-based alpha therapy using 225 Ac-PSMA-I&T provides treatment for
metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177 Lu-PSMA …
metastatic castration-resistant prostate cancer (mCRPC), even after the failure of 177 Lu-PSMA …